Skip to Main Content

Good morning, everyone, and welcome to another working week. The weekend respite went by quickly, yes? Well, this was to be expected. After all, time never stands still. This, of course, is a good reminder to keep busy, and we are doing so with the help of a few cups of stimulation. We will interrupt our usual programming, however, at midday for an appearance on a panel, but return later to resume our usual routine. Meanwhile, here are some tidbits. Have a great day and do keep in touch …

Alexion Pharmaceuticals said its chief executive and chief financial officer have left, as a previously disclosed internal accounting investigation nears completion. Two months ago, a former employee alleged fraud in connection with its Soliris rare disease drug, which generated $2.6 billion in sales in 2015. Delayed quarterly filings are now expected next month or sooner. Board member and former AstraZeneca chief executive David Brennan will become interim CEO.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.